IMNM · Immunome, Inc.
$24.95
-0.06% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-10.1
Dividend yield
—
Beta
2.13
Avg volume
1M
Employees
0K
Daily Change %
-0.06%
5 Days Change
-2.39%
10 Days Change
-4.71%
30 Days Change
-0.50%
60 Days Change
11.86%
Month to Day Change
-3.49%
Year to Day Change
21.60%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMNM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
Barclays
Overweight$36.00
+44.2% vs priceGoldman Sachs
Buy$26.00
+4.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-08-12 | Truist Securities | Maintains | Buy | $37.00 → $38.00 |
| 2026-08-12 | Wedbush | Maintains | Outperform | $31.00 → $35.00 |
| 2026-07-21 | Wedbush | Reiterates | Outperform | $31.00 |
| 2026-06-12 | Wedbush | Reiterates | Outperform | $31.00 |
| 2026-05-28 | Truist Securities | Maintains | Buy | $36.00 → $37.00 |
| 2026-05-28 | Barclays | Initiates | Overweight | $0.00 → $36.00 |
| 2026-05-15 | Leerink Partners | Maintains | Outperform | $37.00 → $33.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.2% below the 50-day MA ($25.27).
- Price vs 200-day MA: Trading 11.0% above the 200-day MA ($22.48).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.54) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($8.99) and high ($29.83).
IMNM Price Chart
Loading chart for IMNM…
Fundamentals
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.